Drug
Trelagliptin clinical trials
Also written SYR-472.
- studies test it
- 18
- open now
- 1
- in phase 3
- 7
- first study started
- 2007
Keep track of what changes. Save the trelagliptin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
18 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 7
- Phase 4
- 4
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Takeda (11) · British University In Egypt (3) · PNS Hafeez - Naval Hospital (1) · Lahore General Hospital (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Khyber Medical College, Peshawar (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses trelagliptin is read from its arms, and is right about nine times in ten.
Testing it · 18
- Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic PatientsEnrolling by invitationPhase 3Khyber Medical College, PeshawarNCT07073768Written as Trelagliptin 100 mg
- Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesActive, not recruitingNot applicablePNS Hafeez - Naval HospitalNCT06913101Written as Trelagliptin 100 mg
- Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesActive, not recruitingNot applicableLahore General HospitalNCT06889909Written as Trelagliptin 100 mg
- Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT03014479Written as Trelagliptin
- Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT03231709Written as Trelagliptin
- A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg TabletsCompletedPhase 1TakedaNCT02372097Written as SYR-472
- Long-term Study of SYR-472CompletedPhase 3TakedaNCT01431807Written as SYR-472
- A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal DiseaseCompletedPhase 3TakedaNCT02512068Written as Trelagliptin 25 mg
- A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 DiabetesCompletedPhase 3TakedaNCT02324569Written as SYR-472
- An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT02771093Written as Trelagliptin
- SYR-472 Open-label StudyCompletedPhase 3TakedaNCT01751360Written as SYR-472
- Double-blind Comparative Study of SYR-472CompletedPhase 3TakedaNCT01632007Written as SYR-472
- Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 DiabetesCompletedPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT03940183Written as Trelagliptin Succinate
- Dose Modification Requirement for Trelagliptin in Egyptian PopulationStatus unknownPhase 4British University In EgyptNCT04374864Written as Trelagliptin
- Omarigliptin in Four Healthy Egyptian VolunteersStatus unknownNot applicableBritish University In EgyptNCT04365907Written as Zafatek tablets
- Omarigliptin & Trelagliptin in Twelve Healthy Egyptian VolunteersCompletedNot applicableBritish University In EgyptNCT03362398Written as Trelagliptin 100 mg
- Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes MellitusCompletedPhase 2TakedaNCT00760344Written as SYR-472
- Efficacy of SYR-472 in Subjects With Type 2 Diabetes MellitusCompletedPhase 2TakedaNCT00653185Written as SYR-472
Codes
What other systems call trelagliptin · ClinicalTrials.gg INT000180
- MeSH (NLM) C000595449trelagliptinOne source NLM
- UNII (FDA) Q836OWG55HTRELAGLIPTINConfirmed FDA, NLM, Wikidata
- Wikidata Q21098968TrelagliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152723TrelagliptinOne source FDA
- DrugBank DB15323One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595449 | trelagliptin | One source NLM |
| UNII (FDA) | Q836OWG55H | TRELAGLIPTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098968 | Trelagliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152723 | Trelagliptin | One source FDA |
| DrugBank | DB15323 | — | One source Wikidata |
Also registered as trelagliptin succinate (UNII 4118932Z90).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.